Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director · HEAD OF R&D, COO-NOVITIUM OPS | February 26, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,056 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 11,116 · Balance 101,056 F1: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Esjay LLC | 431,920 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 431,920 F2: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. |
| Common StockSEC Table I · non-derivative | IndirectHeld by SS Pharma LLC | 5,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,000 F3: The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
F2: The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
F3: The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2023 Filed Oct 19, 2023 20:28 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,242 | $57.78 | $360,662.76 |
DisclosureSEC source: 0001870913-23-000011 · wk-form4_1697747306.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,042,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.15 to $58.41, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 20:28 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 8,758 | $58.53 | $512,605.74 |
DisclosureSEC source: 0001870913-23-000011 · wk-form4_1697747306.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,048,862 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $58.03 to $59.47, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 20:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 13,063 | $58.31 | $761,703.53 |
DisclosureSEC source: 0001870913-23-000009 · wk-form4_1697574720.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,057,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.75 to $58.88, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 20:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,937 | $57.58 | $687,332.46 |
DisclosureSEC source: 0001870913-23-000009 · wk-form4_1697574720.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,070,683 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.36 to $58.00, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| September 19, 2023 Filed Sep 19, 2023 21:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 25,333 | $61.23 | $1,551,139.59 |
DisclosureSEC source: 0001870913-23-000007 · wk-form4_1695158086.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,082,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.63 to $61.69, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 21:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 8,425 | $61.64 | $519,317.00 |
DisclosureSEC source: 0001870913-23-000007 · wk-form4_1695158086.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,107,953 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $61.23 to $62.94, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 21:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 16,242 | $62.81 | $1,020,160.02 |
DisclosureSEC source: 0001870913-23-000007 · wk-form4_1695158086.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,116,378 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $62.01 to $63.82, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 20:29 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 25,000 | $63.37 | $1,584,250.00 |
DisclosureSEC source: 0001870913-23-000005 · wk-form4_1693427333.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,132,620 F3 · price: Reflects the weighted average price of sales on August 29, 2023. The shares were sold in multiple transactions at prices ranging from $62.4877 to $63.92, inclusive. F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:29 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 25,000 | $63.06 | $1,576,500.00 |
DisclosureSEC source: 0001870913-23-000005 · wk-form4_1693427333.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,157,620 F1 · price: Reflects the weighted average price of sales on August 28, 2023. The shares were sold in multiple transactions at prices ranging from $62.57 to $64.64, inclusive. F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 23:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 22,110 | $61.60 | $1,361,976.00 |
DisclosureSEC source: 0001870913-23-000003 · wk-form4_1692227210.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,182,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.81 to $62.59, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 23:07 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 27,890 | $61.15 | $1,705,473.50 |
DisclosureSEC source: 0001870913-23-000003 · wk-form4_1692227210.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,204,730 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.12 to $62.58, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 21, 2023 Filed Jul 21, 2023 23:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,500 | $52.56 | $604,440.00 |
DisclosureSEC source: 0001104659-23-083131 · tm2321830-1_4seq1.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,232,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.10 to $53.32, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 23:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,000 | $51.52 | $309,120.00 |
DisclosureSEC source: 0001104659-23-083131 · tm2321830-1_4seq1.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,244,120 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.00 to $52.08, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 23:15 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,969 | $51.48 | $307,284.12 |
DisclosureSEC source: 0001104659-23-083131 · tm2321830-1_4seq1.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,250,120 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.95 to $52.28, inclusive. The reporting person undertakes to provide to ANI Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4 and 5 to this Form 4. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 00:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 6,700 | $51.84 | $347,328.00 |
DisclosureSEC source: 0001104659-23-082112 · tm2321566-1_4seq1.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,256,089 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.62 to $52.38, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 00:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 9,831 | $51.06 | $501,970.86 |
DisclosureSEC source: 0001104659-23-082112 · tm2321566-1_4seq1.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,262,789 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $49.77 to $51.66, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $50.43 | $504,300.00 |
DisclosureSEC source: 0001104659-23-082112 · tm2321566-1_4seq1.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,272,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $49.98 to $50.83, inclusive. The reporting person undertakes to provide to ANI Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2,4 and 5 to this Form 4. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 23, 2023 Filed Jun 24, 2023 00:01 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 10,000 | $51.49 | $514,900.00 |
DisclosureSEC source: 0001104659-23-074399 · tm2319615-2_4aseq1.xml · nonDerivative · entry 5 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,282,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.99 to $52.08, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 00:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 13,500 | $51.38 | $693,630.00 |
DisclosureSEC source: 0001104659-23-073894 · tm2319370-1_4seq1.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,407 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.85 to $51.84, inclusive. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:01 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 13,500 | $51.38 | $693,630.00 |
DisclosureSEC source: 0001104659-23-074399 · tm2319615-2_4aseq1.xml · nonDerivative · entry 4 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,292,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.85 to $51.84, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 00:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,843 | $51.95 | $615,243.85 |
DisclosureSEC source: 0001104659-23-073894 · tm2319370-1_4seq1.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.13 to $52.56, inclusive. Read SEC document |
| June 21, 2023 Filed Jun 24, 2023 00:01 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 11,843 | $51.95 | $615,243.85 |
DisclosureSEC source: 0001104659-23-074399 · tm2319615-2_4aseq1.xml · nonDerivative · entry 3 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,306,120 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.13 to $52.56, inclusive. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| June 20, 2023 Filed Jun 23, 2023 00:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,657 | $51.93 | $761,138.01 |
DisclosureSEC source: 0001104659-23-073894 · tm2319370-1_4seq1.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,750 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.63 to $52.80, inclusive. The reporting person undertakes to provide to ANI Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4 to this Form 4. Read SEC document |
| June 20, 2023 Filed Jun 24, 2023 00:01 UTC Amendment | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 14,657 | $51.93 | $761,138.01 |
DisclosureSEC source: 0001104659-23-074399 · tm2319615-2_4aseq1.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Plan reported Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,317,963 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.63 to $52.80, inclusive. The reporting person undertakes to provide to ANIPharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5 and 6 to this Form 4. F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:08 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 11,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041740 · tm2311710-8_4seq1.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,407 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:08 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 17,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041740 · tm2311710-8_4seq1.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,829 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023. Read SEC document |
| March 17, 2022 Filed Mar 22, 2022 01:58 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 5,000 | $27.65 | $138,251.50 |
DisclosureSEC source: 0001415889-22-003247 · form4-03212022_060303.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Not disclosed Ownership: Indirect · Held by SS Pharma LLC Disclosed balance after: 5,000 F1 · price: The shares were acquired in multiple trades at prices ranging from $27.36 to $28.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC. Read SEC document |
| March 17, 2022 Filed Mar 22, 2022 01:58 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 5,000 | $27.65 | $138,251.50 |
DisclosureSEC source: 0001415889-22-003247 · form4-03212022_060303.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,460 F1 · price: The shares were acquired in multiple trades at prices ranging from $27.36 to $28.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:46 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 1,332,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-005444 · form4-11232021_011120.xml · nonDerivative · entry 2 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Esjay LLC Disclosed balance after: 1,332,620 F2 · price: In accordance with the Merger Agreement, an aggregate of 6,954,750 Company Interests of Novitium held by Esjay LLC were converted into 1,332,620 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:46 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 13,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-005444 · form4-11232021_011120.xml · nonDerivative · entry 1 Shanmugam Muthusamy · CIK 0001870913 · Director · HEAD OF R&D, COO-NOVITIUM OPS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,460 F1 · price: On November 19, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of March 8, 2021 (as amended, supplemented or modified from time to time, the "Merger Agreement"), by and among ANI Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Novitium Pharma LLC, a Delaware limited liability company ("Novitium"), and the other parties thereto, the Issuer completed its acquisition of Novitium. In accordance with the Merger Agreement, an aggregate of 70,250 Company Interests of Novitium held by the Reporting Person were converted into 13,460 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.